SAFC preparing for inevitable shift to cell culture vaccines

By Nick Taylor

- Last updated on GMT

Related tags: Influenza

SAFC Pharma is preparing for the shift towards cell culture-based vaccines, while still supplying and growing in the traditional sector, to ensure it can grow in coming years, according to a company director.

Speaking to in-PharmaTechnologist David Backer, director of business development and marketing at SAFC Pharma, said that the level of funds the US government has put into cell culture means it is certain to become mainstream.

Consequently, SAFC is preparing for this shift and equipping itself to provide products and services for next generation vaccines. This will ensure it can meet the changing demands of the seasonal flu market, as well as dealing with pandemics as they occur, and continue growing.

Related news

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars